JP2002522512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002522512A5 JP2002522512A5 JP2000564666A JP2000564666A JP2002522512A5 JP 2002522512 A5 JP2002522512 A5 JP 2002522512A5 JP 2000564666 A JP2000564666 A JP 2000564666A JP 2000564666 A JP2000564666 A JP 2000564666A JP 2002522512 A5 JP2002522512 A5 JP 2002522512A5
- Authority
- JP
- Japan
- Prior art keywords
- dextran
- leptin
- conjugate
- moiety
- moieties
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940039781 leptin Drugs 0.000 description 62
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical group O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 37
- 150000001413 amino acids Chemical group 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 102000016267 Leptin Human genes 0.000 description 10
- 108010092277 Leptin Proteins 0.000 description 10
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 10
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9619498P | 1998-08-10 | 1998-08-10 | |
| US60/096,194 | 1998-08-10 | ||
| US37068499A | 1999-08-09 | 1999-08-09 | |
| US09/370,684 | 1999-08-09 | ||
| PCT/US1999/018129 WO2000009165A1 (en) | 1998-08-10 | 1999-08-10 | Dextran-leptin conjugates, pharmaceutical compositions and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002522512A JP2002522512A (ja) | 2002-07-23 |
| JP2002522512A5 true JP2002522512A5 (https=) | 2006-10-05 |
| JP4199421B2 JP4199421B2 (ja) | 2008-12-17 |
Family
ID=26791397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000564666A Expired - Lifetime JP4199421B2 (ja) | 1998-08-10 | 1999-08-10 | デキストラン−レプチン結合体、医薬組成物および関連方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1107793B1 (https=) |
| JP (1) | JP4199421B2 (https=) |
| AT (1) | ATE280588T1 (https=) |
| AU (1) | AU5347099A (https=) |
| CA (1) | CA2337667C (https=) |
| DE (1) | DE69921486T2 (https=) |
| ES (1) | ES2228082T3 (https=) |
| PT (1) | PT1107793E (https=) |
| WO (1) | WO2000009165A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| ES2257287T3 (es) * | 1999-02-12 | 2006-08-01 | Amgen Inc. | Composiciones de leptina glicosiladas y metodos relacionados. |
| GB0116860D0 (en) * | 2001-07-10 | 2001-09-05 | Univ Montfort | Gel compositions |
| JP2007530569A (ja) * | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | 化学修飾タンパク質組成物及び方法 |
| US8642543B2 (en) | 2005-09-07 | 2014-02-04 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
| US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
| CN101143894A (zh) * | 2007-06-22 | 2008-03-19 | 中国药科大学 | 高效抑制血管生成多肽及其物理化学修饰方法和应用 |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
| RU2650646C2 (ru) | 2012-09-27 | 2018-04-16 | Дзе Чилдрен'З Медикал Сентер Корпорейшн | Соединения, предназначенные для лечения ожирения, и способы их применения |
| SI3074033T1 (sl) | 2013-11-26 | 2019-03-29 | The Children's Medical Center Corporation | Spojine za zdravljenje debelosti in postopki njihove uporabe |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| CA3036551A1 (en) | 2016-09-12 | 2018-03-15 | Aegerion Pharmaceuticals, Inc. | Methods of detecting anti-leptin neutralizing antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6688896A (en) * | 1995-08-17 | 1997-03-12 | Amgen, Inc. | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
| AU2670897A (en) * | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
-
1999
- 1999-08-10 JP JP2000564666A patent/JP4199421B2/ja not_active Expired - Lifetime
- 1999-08-10 EP EP99939127A patent/EP1107793B1/en not_active Expired - Lifetime
- 1999-08-10 AU AU53470/99A patent/AU5347099A/en not_active Abandoned
- 1999-08-10 AT AT99939127T patent/ATE280588T1/de active
- 1999-08-10 CA CA002337667A patent/CA2337667C/en not_active Expired - Lifetime
- 1999-08-10 DE DE69921486T patent/DE69921486T2/de not_active Expired - Lifetime
- 1999-08-10 ES ES99939127T patent/ES2228082T3/es not_active Expired - Lifetime
- 1999-08-10 PT PT99939127T patent/PT1107793E/pt unknown
- 1999-08-10 WO PCT/US1999/018129 patent/WO2000009165A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002527052A5 (https=) | ||
| JP2002522512A5 (https=) | ||
| US6617306B2 (en) | Carrier for in vivo delivery of a therapeutic agent | |
| JP6227629B2 (ja) | ヒトアミリン類似体 | |
| CA2345027A1 (en) | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility | |
| JP2008524117A5 (https=) | ||
| JP2011524420A5 (https=) | ||
| MX2011003788A (es) | Mutantes fgf21 y uso de los mismos. | |
| JP2010534486A5 (https=) | ||
| EP0651765A1 (en) | Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis | |
| US20020147142A1 (en) | Methods and reducing or maintaining reduced levels of blood lipids using OB protein compositions | |
| JP2008540565A5 (https=) | ||
| KR950701937A (ko) | 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체(glucagon-like peptide and insulinotropin derivatives) | |
| JP2005516885A5 (https=) | ||
| WO2000005260A1 (en) | Peptide analogues of pacap | |
| RU2007110981A (ru) | Урокортин iii и его использование | |
| JP2010513327A5 (https=) | ||
| JP2008518026A5 (https=) | ||
| JP2003534287A5 (https=) | ||
| JP2009520758A5 (https=) | ||
| JP2002525081A5 (https=) | ||
| JP2009502803A5 (https=) | ||
| WO1997038014A1 (en) | Fibulin pharmaceutical compositions and related methods | |
| ZA200508063B (en) | Peptides for use in treating obersity | |
| JP2006523708A5 (https=) |